Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Priority claimed from PCT/EP2013/069892external-prioritypatent/WO2014048939A1/fr
Publication of MA42864A1publicationCriticalpatent/MA42864A1/fr
Publication of MA42864B1publicationCriticalpatent/MA42864B1/fr
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
MA42864A2012-09-262013-09-25Composes d’éther cyclique-pyrazol-4-yl-heterocyclyl-carboxamide et procédés d'utilisation
MA42864B1
(fr)
Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.